Mabion Revenue
Pharmaceutical Manufacturing • 
Konstantynów Łodzki, Łódź Voivodeship, Poland • 101-200 Employees
Mabion revenue & valuation
| Annual revenue | $18,300,000 |
| Revenue per employee | $102,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $58,600,000 |
| Total funding | No funding |
Key Contact at Mabion
Company overview
| Headquarters | ul. gen. Mariana Langiewicza 60, Konstantynów Łódzki, łódzkie, Poland 95-050, PL |
| Phone number | +48422077890 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Biologics Production, Recombinant Protein Production, Monoclonal Antibody Production, Protein Characterization, Biologics Development, Biologics Manufacturing, Biosimilar Development, Biologics Process Development, Biologics Cdmo, Biosimilar Manufacturing, Biologics Testing, Biologics Characterization, Biopharma Cdmo, Antibodies Development, Biologics Analytics, Biologics Stability Studies, Biosimilar Cdmo, Cdmo Biologics, European Cdmo, Gmp Cdmo |
| Founded | 2007 |
| Employees | 101-200 |
| Socials |
Mabion Email Formats
Mabion uses 5 email formats. The most common is {first name}.{last name} (e.g., john.doe@mabion.eu), used 72.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@mabion.eu | 72.5% |
{first initial}.{last name} | j.doe@mabion.eu | 24.6% |
{first initial}.{first initial} | j.j@mabion.eu | 1.4% |
{last name}.{last name} | doe.doe@mabion.eu | 1.4% |
About Mabion
Mabion S.A. is a Polish biopharmaceutical CDMO providing extensive drug development and biomanufacturing services to pharmaceutical and Biotech companies globally. We offer services for clinical and commercial manufacture of recombinant protein therapeutics, including process and analytical development services, GMP manufacture of Drug Substance (from small scale up to 4 x 2.000 liter single-use bioreactor sizes), GMP manufacture of Drug Product in our state-of-the-art filling line and an extensive set of analytics and QC tests. This is supported by a robust quality assurance and regulatory affairs department. In addition to our regular CDMO offering, Mabion also took part in the global fight against the coronavirus pandemic by signing a record contract with Novavax Inc. in October 2021 for the commercial production of the antigen for their COVID-19 vaccine. This partnership has proven to be very successful, leading to several subsequent additional services offered by Mabion, augmenting the main commercial-scale manufacturing contract. We aim to establish ourselves as a key global player in the global contract manufacturing and contract drug development market offering a broad range of high-quality integrated services to the Biotech and pharmaceutical market. Mabion is a public Company, listed on the Warsaw Stock Exchange (WSE: MAB). For more information about the Company, please visit www.mabion.eu
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Mabion has 39 employees across 10 departments.
Departments
Number of employees
Funding Data
Mabion has never raised funding before.
Mabion Tech Stack
Discover the technologies and tools that power Mabion's digital infrastructure, from frameworks to analytics platforms.
Web servers
Live chat
Security
Tag managers
Miscellaneous
Form builders
Miscellaneous
Programming languages
Blogs
JavaScript libraries
JavaScript libraries
Analytics
United Kingdom
Canada
United States
France
RomaniaFrequently asked questions
4.8
40,000 users
